Evidence map›Paper›PMID 33772550›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study.

Davit Baliashvili, Neel R Gandhi, Soyeon Kim, Michael Hughes, Vidya Mave, Alberto Mendoza-Ticona, Pedro Gonzales, Kim Narunsky, Poongulali Selvamuthu, Sharlaa Badal-Faesen and 8 more

Open access · greenAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Capturing RecentTropical medicine and infectious disease · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 4 countries.

Davit BaliashviliEmory Rollins School of Public Health, Atlanta, Georgia, USA.
Neel R GandhiEmory Rollins School of Public Health, Atlanta, Georgia, USA.
Soyeon KimFrontier Science Foundation, Brookline, Massachusetts, USA.
Michael HughesHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Vidya MaveByramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, Maharashtra, India.
Alberto Mendoza-TiconaAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Pedro GonzalesAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Kim NarunskyUCT Lung Institute, Cape Town, South Africa.
Poongulali SelvamuthuChennai Antiviral Research and Treatment (CART) Clinical Research Site, Infectious Diseases Medical Center, Voluntary Health Services, Chennai, India.
Sharlaa Badal-FaesenClinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Caryn UptonTASK Applied Science, Cape Town, South Africa.
Linda NainiSocial and Scientific Systems, Inc., Silver Spring, Maryland, USA.
Elizabeth SmithNational Institutes of Health, Bethesda, Maryland, USA.
Amita GuptaJohns Hopkins University, Department of Medicine, Baltimore, Maryland, USA.
Gavin ChurchyardAurum Institute, Parktown, South Africa.
Susan SwindellsUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.
Anneke HesselingDesmond Tutu TB Centre, Stellenbosch University, Tygerberg, South Africa.
N Sarita ShahEmory Rollins School of Public Health, Atlanta, Georgia, USA.
Emory University · USAsociación Civil Impacta Salud y Educación · PEUniversity of the Witwatersrand · ZAFrontier Science & Technology Research Foundation · USGovernment Medical College · INHarvard University · USJohns Hopkins University · USNational Institutes of Health · USSocial and Scientific Systems (United States) · USStellenbosch University · ZATask Applied Science · ZAUniversity of Nebraska Medical Center · USVoluntary Health Services Hospital · IN

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Botswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTU Y18 SupplementUM1AI069456 · NIAID · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2012 to 2026
$29.4M
Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaUM1AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI Shaun Barnabas, Anneke Catharina Hesseling · 2012 to 2026
$21.5M
Role of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 2014 to 2020
$20.1M
Immunology/Pathology CoreP30AI051519 · NIAID · YESHIVA UNIVERSITY · PI GOLDSTEIN, HARRIS · 2003 to 2013
$18.6M
Aurum Clinical Trials UnitUM1AI154463 · NIAID · AURUM INSTITUTE NPC · PI Gavin John Churchyard · 2021 to 2026
$8.1M
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentFIC NIH HHS D43 TW007124National Institute of Allergy and Infectious DiseasesNational South African Research FoundationNIAID NIH HHS P30 AI051519NIAID NIH HHS U19 AI111211NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069456NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069521NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI106716NIAID NIH HHS UM1 AI154463NIMH NIH HHS
6 · The paper itself

Abstract

backgroundSome contacts of patients with tuberculosis remain negative on tests for tuberculosis infection, despite prolonged exposure, suggesting they might be resistant to Mycobacterium tuberculosis infection. The objective of this multinational study was to estimate the proportion of household contacts resistant to M. tuberculosis (resisters).

methodsWe conducted a longitudinal study enrolling index patients enrolled in treatment for pulmonary multidrug- or rifampin-resistant tuberculosis and their household contacts. Contacts were tested for tuberculosis infection with a tuberculin skin test (TST) and interferon-gamma release assay (IGRA) at baseline and after 1 year. Exposure was quantified based on index patients' infectiousness, index patient and household contact interaction, and age. We explored multiple definitions of resistance to tuberculosis infection by varying TST negativity cutoffs (0 vs <5 mm), classification of missing test results, and exposure level.

resultsIn total, 1016 contacts were evaluated from 284 households; 572 contacts aged ≥5 years had TST and longitudinal IGRA results available. And 77 (13%) or 71 (12%) contacts were classified as resisters with a <5 mm or 0 mm TST threshold, respectively. Among 263 highly exposed contacts, 29 (11%) or 26 (10%) were classified as resisters using TST cutoffs of <5 mm and 0 mm, respectively. The prevalence of resisters did not differ substantially by sex, age, human immunodeficiency virus (HIV) coinfection, or comorbid conditions.

conclusionsAt least 10% of household contacts can be classified as resistant to tuberculosis infection, depending on the definition used, including those with high exposure. Further studies to understand genetic or immunologic mechanisms underlying the resister phenotype may inform novel strategies for therapeutics and vaccines.

Indexed as

Latent TuberculosisMycobacterium tuberculosisTuberculosisHumansInterferon-gamma Release TestsLongitudinal StudiesTuberculin Testexposureinfectionresisterstuberculosis

Identifiers

PMID33772550
PMCPMC8442792
OpenAlexW3137908599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.